Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

The long tail of oncogenic drivers in prostate cancer

(2018) Joshua Armenia et al.   NATURE GENETICS

The what, when, and why of human prostate cancer xenografts

(2018) W. Nathaniel Brennen et al.   PROSTATE

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an­­d Serve as Models for Evaluating Cancer Therapeutics

(2017) Holly M. Nguyen et al.   PROSTATE

Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program

(2017) Alberto J. Taurozzi et al.   PLoS One

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

(2016) Akash Kumar et al.   NATURE MEDICINE

Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice

(2015) Christian Wetterauer et al.   PROSTATE

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

(2014) X. Wan et al.   Science Translational Medicine

Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naïve prostate cancer and are elevated in castration-resistant disease

(2013) Tobias Zellweger et al.   ENDOCRINE-RELATED CANCER

A preclinical xenograft model of prostate cancer using human tumors

(2013) Mitchell G Lawrence et al.   Nature Protocols

Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor

(2010) Dong Lin et al.   PROSTATE

Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts

(2009) Donald J. Vander Griend et al.   PROSTATE

Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

(2008) W M van Weerden et al.   BRITISH JOURNAL OF CANCER